173 related articles for article (PubMed ID: 9303183)
1. Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA.
Fell PL; Hudson AJ; Reynolds MA; Usman N; Akhtar S
Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):319-26. PubMed ID: 9303183
[TBL] [Abstract][Full Text] [Related]
2. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
Phylactou LA; Tsipouras P; Kilpatrick MW
Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.
Bramlage B; Alefelder S; Marschall P; Eckstein F
Nucleic Acids Res; 1999 Aug; 27(15):3159-67. PubMed ID: 10454613
[TBL] [Abstract][Full Text] [Related]
4. Allosteric hammerhead ribozyme TRAPs.
Burke DH; Ozerova ND; Nilsen-Hamilton M
Biochemistry; 2002 May; 41(21):6588-94. PubMed ID: 12022862
[TBL] [Abstract][Full Text] [Related]
5. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody.
Hudson AJ; Normand N; Ackroyd J; Akhtar S
Int J Pharm; 1999 May; 182(1):49-58. PubMed ID: 10332074
[TBL] [Abstract][Full Text] [Related]
6. Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages.
Shimayama T; Nishikawa F; Nishikawa S; Taira K
Nucleic Acids Res; 1993 Jun; 21(11):2605-11. PubMed ID: 8332458
[TBL] [Abstract][Full Text] [Related]
7. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection.
Tang J; Breaker RR
RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650
[TBL] [Abstract][Full Text] [Related]
8. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
[TBL] [Abstract][Full Text] [Related]
9. A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes.
Mercatanti A; Rainaldi G; Mariani L; Marangoni R; Citti L
J Comput Biol; 2002; 9(4):641-53. PubMed ID: 12323098
[TBL] [Abstract][Full Text] [Related]
10. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
11. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro.
Kisich KO; Freedland SJ; Erickson KL
Biochem Biophys Res Commun; 1997 Jul; 236(1):205-11. PubMed ID: 9223453
[TBL] [Abstract][Full Text] [Related]
12. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
Sioud M
Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme.
Luzi E; Papucci L; Schiavone N; Donnini M; Lapucci A; Tempestini A; Witort E; Nicolin A; Capaccioli S
Cancer Gene Ther; 2003 Mar; 10(3):201-8. PubMed ID: 12637941
[TBL] [Abstract][Full Text] [Related]
14. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
Sioud M
J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
[TBL] [Abstract][Full Text] [Related]
15. Facilitated reduction of beta-amyloid peptide precursor by synthetic oligonucleotides in COS-7 cells expressing a hammerhead ribozyme.
Denman RB; Smedman M; Abraham M; Chen-Hwang MC; Currie JR
Arch Biochem Biophys; 1997 Dec; 348(1):82-90. PubMed ID: 9390177
[TBL] [Abstract][Full Text] [Related]
16. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III.
Denman RB; Smedman M; Kung L
Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076
[TBL] [Abstract][Full Text] [Related]
17. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
Dorai T; Olsson CA; Katz AE; Buttyan R
Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
[TBL] [Abstract][Full Text] [Related]
18. Improvement of hammerhead ribozymes cleaving mdr-1 mRNA.
Palfner K; Kneba M; Hiddemann W; Bertram J
Biol Chem Hoppe Seyler; 1995 May; 376(5):289-95. PubMed ID: 7544982
[TBL] [Abstract][Full Text] [Related]
19. Design and expression of chimeric U1/ribozyme transgenes.
Abounader R; Montgomery R; Dietz H; Laterra J
Methods Mol Biol; 2004; 252():209-19. PubMed ID: 15017051
[TBL] [Abstract][Full Text] [Related]
20. Novel cleavage of a hammerhead ribozyme targeted to beta-amyloid peptide precursor mRNA.
Denman R; Miller DL
Arch Biochem Biophys; 1993 Sep; 305(2):392-400. PubMed ID: 8373177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
